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We have previously described a serum test to quantitate the
level of a circulating breast cancer associated antigen
[Mammary Serum Antigen (MSA)], based on the anti-breast
cancer monoclonal antibody 3E1.2 (Stacker et al., 1985,
1987; Tjandra et al., 1988). Testing by the immuno-
peroxidase method has shown that the 3E1.2 antibody reacts
with >90% of breast cancers, and to a lesser extent with
normal breast epithelium and other tissues (Stacker et al.,
1985). It has previously been established that MSA was
elevated (>300IU) in about 70% of patients with localised
and in 90% of patients with advanced breast cancer com-
pared to normal individuals or patients with benign breast
disease (Stacker et al., 1987; Tjandra et al., 1988). In
addition, changes in MSA level have been shown to correlate
with the clinical course and precede disease progression
(Tjandra et al., 1988). In a preliminary study, MSA measure-
ment was also found to be more sensitive than the currently
available tumour markers (CA15-3 and CEA) for the detec-
tion of breast cancer (Sacks et al., 1987; Stacker et al., 1988)
but again did not detect all Stage I breast cancers. There is
no obvious reason why MSA level was not elevated in all
subjects with breast cancer, but possibilities include antigenic
heterogeneity and some tumours may not react with 3E1.2
antibody (Albino et al., Stacker et al., 1985); tumour size,
degree of tumour differentiation and histological subtype
may also be important. To determine if there were any
special histological or immunohistological features of sub-
jects with normal or raised MSA levels, a retrospective study
of patients with Stage I (node negative) breast cancer was
conducted.
Serum samples were obtained from 85 patients (ranging in
age from 29-72yrs) with Stage I (node negative) breast can-
cer, subsequently confirmed histologically (Bearhs & Myers,
1983). The MSA levels were determined and a level of
300IU was considered to be the upper limit of normal (mean
+2 s.d.) (Stacker et al., 1987).
The size of the primary breast cancer (excluding
carcinoma-in-situ) was defined as the greatest dimension of
the tumour measured by the pathologist. Tumour grade was
assessed according to the Bloom & Richardson grading
system of the haematoxylin and eosin-stained sections of the
primary breast cancer of 65/85 patients and was categorised
as grade 1 (well differentiated), grade 2 (moderately differen-
tiated) and grade 3 (poorly differentiated) carcinoma of
ductal type (Bloom & Richardson, 1957); three of 85 cases
had carcinoma-in-situ (CIS) and the remaining 17 patients
were considered to have a non-ductal carcinoma on histo-
logical examination.
Immunoperoxidase staining with 3E1.2 MoAb was also
performed in the same 65/68 cases with invasive ductal
carcinoma and the sections were then assessed by light
microscopy to estimate the percentage of carcinoma cells
stained (Stacker et al., 1985; Muir et al., 1987). The sections
in which there was no staining scored 0, up to 25% of
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carcinoma cells stained scored 1, 26-50% scored 2, 51-75%
scored 3 and >75% scored 4. The Chi squared test was used
to assess associations between two variables and the logistic
model was used to examine the joint effects of variables on
MSA level (Cox, 1970).
The distribution of characteristics evaluated for an asso-
ciation with MSA level in patients with Stage I breast cancer
are listed in Table I. It was apparent that MSA level had a
significant association with tumour size (P< 0.01) and a weak
association with the tumour grade (0.1 >P>0.05). There was
no significant association with the histological subtype of
tumour (P>0.5) although the number of cases was small.
Primary invasive ductal breast carcinomas (n =65) were
also examined by the immunoperoxidase technique for the
expression of antigen recognised by MoAb 3E1.2: it was
positive (>25% of carcinoma cells stained) on the vast
majority (58/65 or 89%) of tissue sections. MSA level had a
significant association with immunoperoxidase staining score
(P<0.01) and this association of MSA level with immuno-
reactivity of the primary breast cancer tissue was further
exemplified by the finding that in 6/7 of the patients whose
primary breast cancer tissue reacted poorly (<25% of
carcinoma cell staining) with 3E1.2 antibody, the serum
MSA level was not elevated. If these seven patients (6 had
tumour size >1cm, 5 had tumour grade .2) are excluded
from the study, the association of MSA level with tumour
size (P<0.01) and grade (P<0.01) were stronger in the
remaining 58 patients. However, in 12/58 patients whose
primary invasive ductal breast carcinoma tissues reacted
strongly with 3E1.2 antibody (>25% of carcinoma cells
stained), normal MSA levels (<300IU) was found; of these,
7/12 had primary breast tumours <1 cm and 9/12 had a
tumour grade of <2. In contrast, no significant association
was found between the immunoperoxidase staining scores
0-4 and tumour grade 1, 2 or 3 (P=0.3) (Table II). Among
cases with invasive ductal carcinoma, the independent effects
of tumour size, tumour grade and immunoperoxidase stain-
ing on MSA level were examined. Using a multivariate
logistic model, the; independent associations with MSA level
were strong for 'tumour size (P<0.05) and immuno-
peroxidase staining score (P<0.01), and weak for tumour
grade (P=0.1). However, two of the three patients with
carcinoma-in-situ (ductal 1, lobular 1) had moderately ele-
vated MSA levels (878 IU and 711 IU respectively) which
indicates that tumour size and grade may not be the sole
determinants of elevation of MSA level.
This is a preliminary study to evaluate the pathological
and immunohistopathological characteristics of patients with
ihe earliest stage (Stage I) of breast cancer and relate them
to MSA level. The immunohistochemical staining patterns of
the MoAb 3E1.2 in breast tissue have been described
previously (Stacker et al., 1985). However, because of stain-
ing heterogeneity, a staining score system based solely on the
percentage of carcinoma cells stained was designed and was
found to have a high degree (90% reproducibility) of inter-
observer correlation (Muir et al., 1987). The serum MSA
level was associated with the expression of the 3E1.2 epitope
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Table I Association of MSA level with certain pathological and immunohistopatho-
logical characteristics in patients with Stage I breast cancer
No. of subjects (%)
Normal Raised
MSA level MSA level Total no. of
(<300IU) (>300IU) subjects
Tumour sizea
<1cm 12(60)C 8(40) 20
1-1.9cm 8 (28) 21(72) 29
2-5cm 5(15) 28(85) 33
Chi-squared P value P<0.01
Tumour types
Invasive ductal 18(28) 47(72) 65
CISb 1(33) 2(67) 3
Other typesc 7(41) 10(59) 17
Chi-squared P value P>0.50
Tumour graded
1 10(42) 14(58) 24
2 6(26) 17(74) 23
3 2(11) 16(89) 18
Chi-squared P value 0.10>P>0.05
Immunoperoxidase
Staining % Carcinoma
score cells stained
0 Nil 1(100) 1
1 <25 5 (83) 1(17) 6
2 26-50 4 (44) 5(56) 9
3 51-75 4 (21) 15(79) 19
4 76-100 4 (13) 26(87) 30
Chi-squared P value P<0.01
aDid not include 3 patients with carcinoma-in-situ; bCarcinoma-in-situ (both ductal
and lobular); CIncluded invasive lobular carcinoma and mucoid carcinoma; dEvalu-
able only in 65 patients with invasive ductal carcinoma; eNumbers in parentheses are
row percentages.
Table II Relationship of the staining score obtained with 3E1.2
antibody to tumour grade in 65 breast carcinomas
Immunoperoxidase No. ofpatients with
tumour gradea
Staining % Carcinoma
score cells stained 1 2 3
0 Nil 0 0 1
1 <25 1 3 2
2 26-50 6 1 2
3 51-75 7 7 5
4 76-100 10 12 8
Chi-squared P value P=0.3
aBloom & Richardson (1957) grading of breast cancer.
on breast cancer tissue: 46/58 (79%) of patients with breast
cancer which had good immunoreactivity (>25% carcinoma
cells stained) with 3E1.2 antibody had elevated MSA level
(>300 IU) whereas 6/7 (86%) of patients whose breast
cancer tissue had poor immunoreactivity (<25% carcinoma
cells stained) with 3E1.2 antibody had low MSA level
(<300 IU). As the detection of MSA in the competitive
enzyme immunoassay is dependent on the 3E1.2 antibody, it
is therefore not surprising that the non-expression or low
expression of 3E1.2 epitope on breast cancer tissue is
associated with low MSA level. However, as 12/58 (21%) of
patients had low MSA level despite the expression of 3E1.2
epitope on breast cancer tissue, as assessed by immuno-
peroxidase staining (staining score .2), it illustrates that the
secretion of MSA into the circulation depends on other
factors such as tumour size and tumour grade. Ten of 17
(59%) of patients with other histological subtypes (lobular
carcinoma and mucoid carcinoma) also had an elevated
MSA level but the number studied was small.
Thus it appears that the MSA level in localised breast
cancer relates particularly to the degree of immuno-
peroxidase staining with MoAb 3E1.2, to tumour size, and
weakly with tumour grade. It is important to note also that
there are other factors, as yet unidentified, responsible for
elevation of serum MSA level as some patients with
carcinoma-in-situ can have elevated MSA level. The findings
of elevated MSA level in cases with carcinoma-in-situ further
support the potential value of MSA assays in breast cancer.
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